Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically on the based on the primary end point, may be published when key planned …

Objectives Platinum-based chemotherapy for advanced non–small-cell lung cancer
(NSCLC) has modest benefit overall, but has the potential to amplify immune responses. In …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Abstract The 1st ESMO Consensus Conference on lung cancer was held in Lugano,
Switzerland on 21 and 22 May 2010 with the participation of a multidisciplinary panel of …

Abstract On October 24, 2016, the US Food and Drug Administration (FDA) approved
pembrolizumab (Keytruda; Merck & Co., Inc., https://www. merck. com) for treatment of …

Objectives While pembrolizumab improves overall survival (OS) in a subset of advanced
nonsmall cell lung cancer (aNSCLC) patients (pts) in clinical trials, individuals with poor …

BACKGROUND First-line therapy for advanced non–small-cell lung cancer (NSCLC) that
lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor …

Introduction In cohort G of KEYNOTE-021 (NCT02039674), first-line pembrolizumab plus
pemetrexed-carboplatin significantly improved the objective response rate and progression …

PURPOSE Pembrolizumab monotherapy is standard first-line therapy for metastatic non–
small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion …